KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Goodwill & Intangibles (2017 - 2026)

Amneal Pharmaceuticals has reported Goodwill & Intangibles over the past 9 years, most recently at $1.2 billion for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 12.85% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 12.85%, while the annual FY2025 figure was $1.2 billion, 12.85% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $1.2 billion at Amneal Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $1.8 billion in Q2 2021 and troughed at $1.2 billion in Q4 2025.
  • A 5-year average of $1.6 billion and a median of $1.6 billion in 2023 define the central range for Goodwill & Intangibles.
  • Biggest five-year swings in Goodwill & Intangibles: increased 1.51% in 2022 and later fell 14.12% in 2025.
  • Year by year, Goodwill & Intangibles stood at $1.8 billion in 2021, then dropped by 3.69% to $1.7 billion in 2022, then dropped by 12.15% to $1.5 billion in 2023, then fell by 10.69% to $1.3 billion in 2024, then fell by 12.85% to $1.2 billion in 2025.
  • Business Quant data shows Goodwill & Intangibles for AMRX at $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.